New therapeutics for the treatment of glycosphingolipid lysosomal storage diseases.
Glycosphingolipid lysosomal storage diseases are a small but challenging group of human disorders to treat. Although these appear to be monogenic disorders where the catalytic activity of enzymes in glycosphingolipid catabolism is impaired, the presentation and severity of disease is heterogeneous....
Auteurs principaux: | Butters, T, Dwek, R, Platt, F |
---|---|
Format: | Journal article |
Langue: | English |
Publié: |
2003
|
Documents similaires
-
Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis.
par: Jeyakumar, M, et autres
Publié: (2002) -
Inhibition of glycosphingolipid biosynthesis: application to lysosomal storage disorders.
par: Butters, T, et autres
Publié: (2000) -
Substrate deprivation: a new therapeutic approach for the glycosphingolipid lysosomal storage diseases.
par: Platt, F, et autres
Publié: (2000) -
New developments in treating glycosphingolipid storage diseases.
par: Platt, F, et autres
Publié: (2005) -
Glycosphingolipid profiling of tissues from mouse models of human lysosomal storage disorders
par: Priestman, D, et autres
Publié: (2008)